Multimodal LLM for Breast Cancer Radiotherapy Target Auto-Contouring and Planning
Multimodal Data Fusion-Based Artificial Intelligence Large Language Model for Automated Target Volume Contouring and Intelligent Treatment Planning in Breast Cancer Radiotherapy: A Multicenter Ambidirectional Cohort Study
Breast cancer remains the most prevalent malignancy among women worldwide, with a continuously increasing incidence. As a crucial component of comprehensive cancer treatment, radiotherapy plays a key role in reducing local recurrence rates and improving overall survival outcomes. However, traditional radiotherapy target volume contouring and treatment planning design rely heavily on clinician expertise, presenting challenges such as prolonged processing time, significant inter-observer variability, and high subjectivity in dose optimization. Although artificial intelligence has made substantial progress in automated contouring and planning, conventional single-modal models still face major limitations. These models struggle to effectively integrate clinical text, tumor biological characteristics, and dose distribution factors, resulting in restricted generalizability. Therefore, developing an intelligent radiotherapy assistance system capable of multimodal data fusion is of high clinical significance to enhance precision and efficiency in breast cancer radiotherapy.
This study aims to develop an innovative breast cancer radiotherapy assistance system based on a multimodal large language model. By integrating multimodal imaging data (including CT, MRI, and ultrasound), pathology reports, and structured electronic health record text, the system realizes end-to-end intelligence from target volume contouring to treatment plan generation. Employing a multicenter, ambidirectional cohort design, the study collects comprehensive clinical data from breast cancer patients who have undergone breast-conserving surgery or mastectomy. Technologically, the system innovatively combines the natural language processing capabilities of large language models with the image analysis strengths of deep learning, utilizing attention mechanisms to achieve deep fusion and interactive comprehension of heterogeneous medical data. Notably, the system breaks through traditional radiotherapy planning workflows by jointly optimizing target contouring and dose planning as a unified pipeline, applying reinforcement learning algorithms to dynamically balance target volume coverage with organ-at-risk protection. The outcomes of this study will provide an important paradigm for the clinical application of AI in radiation oncology and advance the field of precision radiotherapy.
調査の概要
状態
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前:Xiaohui Zhao, MD
- 電話番号:+86-13828491190
- メール:zhaoxh27@mail.sysu.edu.cn
研究場所
-
-
Guangdong
-
Guangzhou、Guangdong、中国、510120
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
コンタクト:
- Xiaohui Zhao, MD
- 電話番号:+86-13828491190
- メール:zhaoxh27@mail.sysu.edu.cn
-
主任研究者:
- Xiaohui Zhao, MD
-
-
参加基準
適格基準
就学可能な年齢
- 子
- 大人
- 高齢者
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The study population includes patients with breast cancer from multiple medical centers. The retrospective cohort comprises patients treated at Sun Yat-sen Memorial Hospital (n=35,000) and external collaborating centers (Shenshan Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Zhoukou Central Hospital, and Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, n=15,000) between January 1, 2002, and October 31, 2025. The prospective test cohort comprises patients prospectively enrolled at Sun Yat-sen Memorial Hospital starting from January 1, 2026 (n=1,000).
説明
Inclusion Criteria:
- Patients with pathologically confirmed breast malignant tumors who require postoperative adjuvant radiotherapy following radical surgery.
- Availability of complete pathology reports.
- Availability of complete imaging examinations and reports (such as CT, MRI, ultrasound, X-ray).
- Availability of standardized clinical medical records.
Exclusion Criteria:
- Patients with missing data.
- Patients with primary multiple cancers.
- Patients receiving salvage or palliative radiotherapy.
- Patients receiving accelerated partial breast irradiation (APBI).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:OTHER
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Retrospective Training and Internal Validation Cohort
Retrospective collection of clinical data, multimodal images (MRI, CT, ultrasound, X-ray), pathology reports, and radiotherapy plans from patients with breast cancer treated at Sun Yat-sen Memorial Hospital between January 1, 2002, and October 31, 2025. This cohort (n=35,000) is used for model training and internal validation of the multimodal LLM-assisted automated contouring and radiotherapy planning system. |
The study evaluates an innovative multimodal large language model (LLM) system designed for automated target volume delineation and intelligent treatment planning in post-operative breast cancer radiotherapy. The system integrates clinical text, multimodal imaging (CT, MRI, ultrasound, X-ray), and pathology data to joint-optimize contouring and dose planning without direct patient intervention. |
|
Retrospective External Validation Cohort
Retrospective collection of data from external collaborative centers (Sun Yat-sen Memorial Hospital Shenzhen Hospital, Zhoukou Central Hospital, and Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology) between January 1, 2002, and October 31, 2025 (total n=15,000). This cohort is used to evaluate the external generalizability and robustness of the multimodal AI model. |
The study evaluates an innovative multimodal large language model (LLM) system designed for automated target volume delineation and intelligent treatment planning in post-operative breast cancer radiotherapy. The system integrates clinical text, multimodal imaging (CT, MRI, ultrasound, X-ray), and pathology data to joint-optimize contouring and dose planning without direct patient intervention. |
|
Prospective Test Cohort
Prospective collection of data from patients with breast cancer treated at Sun Yat-sen Memorial Hospital starting from January 1, 2026 (n=1,000). This cohort undergoes double-blind evaluation to prospectively test the performance of the multimodal LLM-driven target volume auto-segmentation and intelligent radiotherapy planning system in clinical practice. |
The study evaluates an innovative multimodal large language model (LLM) system designed for automated target volume delineation and intelligent treatment planning in post-operative breast cancer radiotherapy. The system integrates clinical text, multimodal imaging (CT, MRI, ultrasound, X-ray), and pathology data to joint-optimize contouring and dose planning without direct patient intervention. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Dice Similarity Coefficient (DSC) of Target Volume Auto-Segmentation
時間枠:Baseline
|
Evaluation of the Dice Similarity Coefficient (DSC) between AI-generated automatic breast cancer target volume contours and expert manual contours. |
Baseline
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
95% Hausdorff Distance (95HD) of Target Volume Auto-Segmentation
時間枠:Baseline
|
Evaluation of the 95% Hausdorff Distance (95HD) between AI-generated automatic breast cancer target volume contours and expert manual contours. |
Baseline
|
|
Intersection over Union (IoU) of Target Volume Auto-Segmentation
時間枠:Baseline
|
Evaluation of the Intersection over Union (IoU) between AI-generated automatic breast cancer target volume contours and expert manual contours. |
Baseline
|
|
Clinical Evaluation Score of Target Volume Auto-Segmentation
時間枠:Baseline
|
Blinded evaluation by radiation oncology experts using the Investigator-Developed Cancer Target Volume Contouring Performance Evaluation Scale, a structured 5-point clinical evaluation scale. The scale assesses five dimensions: laterality accuracy (0 to 1 point), radiotherapy type suitability (0 to 1 point), target volume definition (0 to 1.5 points), coverage (0 to 1 point), and structural integrity (0 to 0.5 points). The total score ranges from a minimum of 0 to a maximum of 5, where higher scores indicate better target volume contouring quality and clinical acceptability. |
Baseline
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Xiaohui Zhao, MD、Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。